Posted by Michael Wonder on 08 Sep 2020
BeyondSpring receives breakthrough therapy designations from both U.S. FDA and China NMPA for plinabulin in chemotherapy-induced neutropenia indication
8 September 2020 - Among the first three innovative drugs to receive breakthrough therapy designations in China.
BeyondSpring today announced that its lead asset, first-in-class agent plinabulin, has received the breakthrough therapy designation for the chemotherapy-induced neutropenia indication from both the U.S. FDA and China’s Center for Drug Evaluation of the National Medical Products Administration.
